Rani Therapeutics Holdings Inc. Class A Common Stock (RANI)

About RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including olig…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

69

Website

www.ranitherapeutics.com/

Fundamentals

1-day range

$0.8024$0.9275

Market cap

$96.76M

P/E (trailing)

—

P/E (forward)

-4.74

EPS (trailing)

$-0.41

Dividend yield

—

Beta

0.77

Avg. volume

895.9K

Forecasts

4 analyst ratings

Rani Therapeutics Holdings Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• RANI

  Rani Therapeutics Holdings Inc. Class A Common Stock

  $0.845

  ▼ 1.05%
  Market cap $96.76MP/E —
  $0.44$3.87
• ALDX

  Aldeyra Therapeutics Inc. Common Stock

  $1.49

  ▼ 3.57%
  Market cap $95.91MP/E —
  $1.07$6.18
• ONCY

  Oncolytics Biotech Inc. Common Stock

  $0.8457

  ▼ 0.51%
  Market cap $95.55MP/E —
  $1.39$1.44
• VRCA

  Verrica Pharmaceuticals Inc. Common Stock

  $5.54

  ▲ 9.27%
  Market cap $92.08MP/E —
  $3.28$9.82
• FBIO

  Fortress Biotech Inc. Common Stock

  $2.77

  ▼ 1.07%
  Market cap $92.02MP/E 0.75
  $2.18$4.53
• NTHI

  NeOnc Technologies Holdings Inc. Common Stock

  $4.69

  ▲ 1.74%
  Market cap $90.77MP/E —
  $3.01$12.99
• RFL

  Rafael Holdings Inc. Class B Common Stock

  $2.52

  ▲ 6.33%
  Market cap $105.04MP/E —
  $1.12$3.96

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
  benzinga · 8/21/2026
• HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
  Benzinga · 8/21/2026
• This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
  Benzinga · 8/18/2026
• Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6
  Benzinga · 8/18/2026
• Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
  Yahoo · 8/16/2026
• Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
  Yahoo · 8/13/2026
• Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate
  Benzinga · 8/13/2026
• Rani Therapeutics Appoints Michelle Gilson to Board of Directors
  Yahoo · 8/4/2026

• Gilson Michelle · August 3, 2026 · Grant

  247.2K
• Mir A. Imran · July 21, 2026 · Buy

  36.0K @ $0.69
• Maestas Nicholas · July 17, 2026 · Grant

  2.00M
• Talat Imran · July 17, 2026 · Buy

  35.0K @ $0.7198
• Alireza Javadi · June 27, 2026 · Tax Withholding

  309 @ $0.74
• Talat Imran · June 27, 2026 · Tax Withholding

  7.9K @ $0.74
• Alireza Javadi · June 3, 2026 · Grant

  805.5K
• Kate McKinley · June 3, 2026 · Grant

  805.5K
• Talat Imran · June 3, 2026 · Grant

  3.80M
• Bailey Vasudev Jaiprakash · May 28, 2026 · Grant

  123.6K
• Rometty Lisa Ann · May 28, 2026 · Grant

  123.6K
• Bassan Abraham · May 28, 2026 · Grant

  123.6K
• Ausiello Dennis A · May 28, 2026 · Grant

  123.6K
• BUTEL JEAN LUC · May 28, 2026 · Grant

  123.6K
• Mir A. Imran · May 28, 2026 · Grant

  123.6K

Institutional Ownership

March 31, 2026

Total shares held

43.92M

Total value held

$32.08M

Institutional holders

72